HomePHIO • NASDAQ
add
Phio Pharmaceuticals Corp
$2.04
Makalipas ang Oras ng Trabaho:(0.98%)+0.020
$2.06
Sarado: Abr 25, 7:12:38 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$2.23
Sakop ng araw
$1.97 - $2.30
Sakop ng taon
$0.97 - $9.79
Market cap
9.75M USD
Average na Volume
5.87M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 689.00K | -10.05% |
Net na kita | -1.63M | 14.20% |
Net profit margin | — | — |
Kita sa bawat share | — | — |
EBITDA | -1.67M | 5.05% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 5.38M | -36.61% |
Kabuuang asset | 5.74M | -38.72% |
Kabuuang sagutin | 1.02M | -37.88% |
Kabuuang equity | 4.72M | — |
Natitirang share | 4.78M | — |
Presyo para makapag-book | 0.82 | — |
Return on assets | -72.14% | — |
Return on capital | -86.57% | — |
Cash Flow
Net change in cash
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -1.63M | 14.20% |
Cash mula sa mga operasyon | -1.37M | 42.15% |
Cash mula sa pag-invest | 8.00K | — |
Cash mula sa financing | 1.36M | -43.61% |
Net change in cash | -8.00K | -124.24% |
Malayang cash flow | -783.25K | 51.92% |
Tungkol
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
Itinatag
2011
Headquarters
Website
Mga Empleyado
5
